What are your top takeaways in Lymphoma from ASH 2025?

1. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial — This trial may change practice by using the combination of BTK-I and Ven without CD20 antibodies. This time-limited option led to MRD, and I would expect a long duration of PFS. This regimen will be very attractive, particularly for young patients.
2. Primary Phase 3 results from the EPCORE FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma — This trial provides a second-line option for subjects with FL that avoids chemotherapy. This becomes an excellent option for those patients who cannot do CAR-T either for medical reasons or f...

1. The EPCORE FL-1 trial randomized patients to R2 vs. epcoritamab-R2. This study indicated that the addition of the CD20/C3 bispecific antibody, epcoritamab, to rituximab and lenalidomide could potentially establish a new standard, given the dramatic improvement in remission duration as compared to the R2 regimen. Given the recent data from the INMIND study, which evaluated the addition of tafasitamab to the R2 regimen, this study could completely rechange the paradigm of 2L FL. With increased use of bispecific abx in the community setting, this could become the new standard of care for those with refractory disease or those with a significant burden of disease at relapse.
2. Given the difficulty in treating frontline DLBCL in older patients, sev...

Here are my top 3 oral presentations from the 2025 ASH meeting (2 for FL and 1 for DLBCL):

1. Primary results from the EPCORE FL-1 phase 3 study of Epcor + len + R vs R2 in patients with R/R FL: Fixed duration of Epcor + len + R showed 79% reduction in the risk of disease progression and death with higher rates and durable responses (CRR of 83%) with benefit consistent across broad patient subgroups. The safety profile was manageable in the outpatient setting and remained consistent with the known toxicities of these agents.
2. Three-year results from the TRANSCEND FL phase 2 study of Liso-Cel in patients with 3L+ FL: outstanding efficacy results across all subgroups, including POD24, bulky disease double refractory and prior bendamustine treatment...

1. Phase III clinical trial EPCORE-FL-1 that compared epcoritamab + lenalidomide + rituximab (Epco-R2) vs R2 as second line for R/R follicular lymphoma. The primary endpoint was. With a median follow-up of about 13-14 months, the PFS, DOR, and CR rates were significantly better with Epco-R2 than R2. This study represents a potential practice-changing regimen for 2L FL in which there is no clear established treatment option. The follow-up is still short, and some patients are still receiving treatment. While we do not expect major differences, a longer follow-up is needed for FL, especially regarding side effects, particularly infections, which are common with BiAbs. Patients in the Epco-R2 had more infections, cytopenias, and COVID-19 infec...